CareDx, Inc.
CDNA
$47.85
+9.47%
CareDx, Inc. is a precision medicine company specializing in the discovery, development, and commercialization of diagnostic solutions for transplant patients, offering a range of testing services, products, and digital tools across the pre- and post-transplant journey. As a market leader in transplant diagnostics, CareDx is distinguished by its proprietary genomics-based tests, including AlloSure and AlloMap, which are widely adopted by transplant centers. The current investor narrative centers on the company's strategic pivot to its high-margin core testing services, following the divestiture of its lower-growth Lab Products division, and a strong Q2 beat with raised full-year guidance that has fueled a sharp rally in the stock.…
CDNA
CareDx, Inc.
$47.85
Related headlines
Investment Opinion: Should I buy CDNA Today?
Rating: Buy. CareDx is a high-growth diagnostics company with a strong strategic position in transplant testing. The recent Q2 beat and raised guidance, combined with a PEG ratio of 0.34, suggest that the stock is undervalued relative to its growth potential. The analyst consensus is 'buy' with an average target price of $35.40, implying a potential upside of -19% from the current price of $43.71 (note: the current price is above the average target, so the upside is negative). However, the high target of $50.00 suggests further upside if the company executes well.
Sign up to view all
CDNA 12-Month Price Forecast
The AI assessment is bullish on CareDx, driven by strong revenue growth, high gross margins, and a favorable PEG ratio. The company's strategic focus on core testing services and recent Q2 beat support a positive outlook. However, the high forward PE and current unprofitability introduce uncertainty, warranting a medium confidence level. The stance would be upgraded to high confidence if the company achieves positive net income and maintains growth, while a downgrade would occur if revenue growth decelerates or margins compress significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CareDx, Inc.'s 12-month outlook, with a consensus price target around $43.67 and implied upside of -8.7% versus the current price.
Average Target
$43.67
0 analysts
Implied Upside
-8.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$35 - $50
Analyst target range
The target price range spans from a low of $21.00 to a high of $50.00, indicating a wide dispersion of views and high uncertainty about the company's future performance. The high target of $50.00 assumes continued strong growth and successful execution of the strategic pivot, while the low target of $21.00 reflects concerns about competitive pressures or margin compression. The wide spread suggests that analysts have divergent opinions on the stock's prospects, and the recent price surge may have been driven by momentum rather than fundamental consensus.
Bulls vs Bears: CDNA Investment Factors
CareDx presents a compelling growth story with strong revenue growth, high gross margins, and a strategic focus on its core testing services. However, the company is currently unprofitable, and the stock has rallied significantly, trading near its 52-week high. The bull case is supported by the PEG ratio of 0.34 and positive analyst sentiment, while the bear case highlights the high forward PE and wide analyst target dispersion. The most important tension is whether the company can translate its revenue growth into sustainable profitability, as the current valuation implies high expectations. If CareDx delivers on its raised guidance and achieves profitability, the stock could continue to rise; otherwise, it may face a sharp correction.
Bullish
- Strong Revenue Growth: CareDx's most recent quarterly revenue is estimated at $507 million (annualized), reflecting a robust growth trajectory. The company's strategic pivot to high-margin core testing services is driving this expansion, with a strong Q2 beat and raised full-year guidance.
- High Gross Margin: The gross margin stands at 66.99%, indicating strong profitability at the gross level. This high margin provides a solid foundation for future operating leverage as the company scales its testing services.
- Undervalued on PEG: The PEG ratio of 0.34 suggests the stock is undervalued relative to its expected growth rate. This implies the market may be pricing in a strong earnings recovery, offering upside potential for investors.
- Positive Analyst Sentiment: Analysts have a 'buy' recommendation with an average target price of $35.40, implying a potential upside from the current price of $43.71. The high target of $50.00 suggests further upside if the company executes well.
Bearish
- Unprofitable Operations: CareDx is currently unprofitable on a net basis, with a net margin of -5.62% and EPS of -$0.02 in the latest quarter. The negative operating margin of -5.53% indicates ongoing operational inefficiencies.
- High Valuation on Forward PE: The forward PE ratio of 38.54x is elevated, implying high growth expectations. If the company fails to meet these expectations, the stock could face significant de-rating.
- Wide Analyst Target Range: The analyst target price range is wide, from $21.00 to $50.00, indicating high uncertainty and divergent views on the company's future performance. This dispersion suggests a risky investment profile.
- Recent Price Surge May Be Overextended: The stock has surged 255.8% over the past year and is trading near its 52-week high of $45.00. This rapid appreciation may have priced in much of the good news, leaving limited upside and increasing the risk of a pullback.
CDNA Technical Analysis
CareDx has exhibited a powerful uptrend over the past year, with the stock price surging 255.8% over the 1-year period. Currently trading at $43.71, the stock is near the upper end of its 52-week range, at approximately 97% of the range (calculated as (43.71 - 11.259) / (45.0 - 11.259) * 100). This positioning near the highs indicates strong momentum and investor confidence, though it also raises the risk of overextension and potential profit-taking.
Beta
2.42
2.42x market volatility
Max Drawdown
-43.9%
Largest decline past year
52-Week Range
$11-$50
Price range past year
Annual Return
+291.6%
Cumulative gain past year
| Period | CDNA Return | S&P 500 |
|---|---|---|
| 1m | +63.9% | +1.7% |
| 3m | +131.2% | +4.7% |
| 6m | +152.8% | +10.4% |
| 1y | +291.6% | +21.9% |
| ytd | +150.0% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CDNA Fundamental Analysis
CareDx's revenue trajectory has been robust, with the most recent quarterly revenue estimated at $507 million (annualized), reflecting a significant growth rate. The company's gross margin stands at 66.99%, indicating strong profitability at the gross level. However, the company is currently unprofitable on a net basis, with a net margin of -5.62% and an EPS of -$0.02 in the latest quarter. The operating margin is also negative at -5.53%, but the trend is improving as the company scales its core testing services and benefits from the divestiture of lower-margin businesses.
Quarterly Revenue
N/A
N/A
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
N/A
Latest Quarter
Free Cash Flow
N/A
Last 12 Months
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CDNA Overvalued?
Given that CareDx has negative trailing earnings (net income < 0), the price-to-sales (PS) ratio is the most appropriate valuation metric. The current PS ratio is 2.64x, which is relatively modest for a high-growth diagnostics company. The forward PE ratio is 38.54x, implying that the market expects significant earnings growth in the coming year. The PEG ratio of 0.34 suggests that the stock is undervalued relative to its expected growth rate, indicating that the market may be pricing in a strong earnings recovery.
PE
-47.1x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-207.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: CareDx is currently unprofitable, with a net margin of -5.62% and an operating margin of -5.53%. The company's negative EPS of -$0.02 indicates that it is still burning cash, though the trend is improving. The debt-to-equity ratio is low at 0.086, indicating a manageable debt burden, but the negative profitability raises concerns about long-term financial sustainability. The company's revenue is concentrated in the United States, which exposes it to domestic healthcare policy changes and reimbursement risks. Additionally, the reliance on a few key testing products (AlloSure and AlloMap) creates product concentration risk; any disruption in these products could significantly impact revenue.
FAQ
The key risks for CareDx include: 1) Financial risk: The company is unprofitable with a net margin of -5.62%, and if it fails to achieve profitability, the stock could decline. 2) Competitive risk: The transplant diagnostics market is competitive, and new entrants could pressure pricing and market share. 3) Macro risk: The stock is highly volatile, with a one-year gain of 255.8% versus the S&P 500's 18.19%, making it sensitive to market sentiment. 4) Company-specific risk: The reliance on a few key products (AlloSure and AlloMap) creates concentration risk. The most severe risk is a decline to the 52-week low of $11.259, representing a -74% downside from the current price.
The 12-month forecast for CareDx is based on three scenarios: Bull case (30% probability) targets $45-$50, driven by strong execution and profitability; Base case (50% probability) targets $35-$45, reflecting balanced growth and margin pressure; Bear case (20% probability) targets $21-$30, due to competitive or operational setbacks. The most likely scenario is the base case, which assumes continued revenue growth but delayed profitability. The key assumption is that CareDx will maintain its growth trajectory while gradually improving margins. Investors should monitor quarterly earnings for signs of progress toward profitability.
Based on the PS ratio of 2.64x, CareDx is trading at a moderate valuation for a high-growth diagnostics company. The forward PE of 38.54x is elevated, but the PEG ratio of 0.34 suggests that the stock is undervalued relative to its expected growth rate. Compared to its own history, the stock has re-rated significantly, trading near its 52-week high. The market is pricing in strong earnings growth, and if the company delivers, the valuation could be justified. However, if growth decelerates, the stock could be considered overvalued. Overall, the valuation appears fair to slightly undervalued based on growth prospects.
CareDx presents a compelling risk/reward profile for growth-oriented investors. The stock has a PEG ratio of 0.34, suggesting it is undervalued relative to its expected growth, and analysts have a 'buy' recommendation with an average target of $35.40. However, the current price of $43.71 is above the average target, implying limited upside based on consensus estimates. The biggest downside risk is the company's unprofitability and the potential for a sharp correction if growth disappoints. For investors with a high risk tolerance and a long-term horizon, CareDx could be a good buy, but it is not suitable for conservative investors seeking immediate returns.
CareDx is better suited for long-term investment due to its high growth potential and the time needed to achieve profitability. The stock is highly volatile, with a beta implied by its 255.8% one-year gain, making it risky for short-term trading. The company does not pay a dividend, so returns depend on capital appreciation. Given the early stage of its strategic pivot and the potential for significant upside, a minimum holding period of 3-5 years is recommended to allow the company to execute its growth plan and reach profitability. Short-term investors may face significant price swings and should be prepared for high volatility.